Drug Profile
Research programme: antibody therapeutics - Adimab/Takeda
Alternative Names: Bispecific antibody therapeutics - Adimab/Takeda; Monoclonal antibody therapeutics - Adimab/TakedaLatest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator Adimab; Takeda
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer